Adebrelimab manufacturers
- Adebrelimab
-
- $247.00
-
2026-07-13
- CAS:2247114-85-6
- Purity: 95.00%
- Supply Ability: 10g
|
| | Adebrelimab Basic information |
| Product Name: | Adebrelimab | | Synonyms: | Adebrelimab;Research Grade Adebrelimab (DHJ70108);Research Grade Adebrelimab;Adebrelimab (anti-PD-L1) | | CAS: | 2247114-85-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Adebrelimab Structure]() |
| | Adebrelimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Adebrelimab Usage And Synthesis |
| Uses | Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC)[1][2]. | | in vivo | Adebrelimab (SHR-1316; 200 μg; three times a week; for 21 days) shows inhibition effects on tumor growth[1]. | Animal Model: | Pathogen free (SPF) BALB/c nude female mice (aged 5-6 weeks) injected with SK-BR-3 cells[1] | | Dosage: | 200 μg | | Administration: | Three times a week; for 21 days | | Result: | Significantly inhibited tumor growth. |
| | References | [1] Zhiwei Liu, et al. The Synergistic Effects of Pyrotinib and SHR-1316 on HER2-positve breast cancer. Research Square. May 19th, 2022.
[2] Wanpu Yan, et al. Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial. J Thorac Oncol. 2022 Sep 30;S1556-0864(22)01822-6. DOI:10.1016/j.jtho.2022.09.222 |
| | Adebrelimab Preparation Products And Raw materials |
|